BUNIN LS, CARNIOL PJ. CERVICAL FACIAL SKIN TIGHTENING WITH AN INFRARED DEVICE. FACIAL PLAST SURG CLIN NORTH AM 2007;15:179-184, VI.

ROY D. NECK REJUVENATION. DERMATOL CLIN 2005;23:469-74, VI.


TREATING PHOTODAMAGE OF THE DÉCOLLETAGE AREA WITH A NOVEL COPPER ZINC MALONATE COMPLEX PLUS HYDROQUINONE AND TRETINOIN

James Leyden, MD
KLG, Inc., Broomall, PA

INTRODUCTION

The majority of clinical research in neck rejuvenation has been focused on minor modifications to existing treatment modalities, such as non-invasive devices, chemical peels, and botulinum toxin. However, neck rejuvenation in the modern era is a highly visible area of concern for many women and men, and the demand for effective and safe therapies that can address the diversity of aging signs is increasing.

In this study, we evaluated the efficacy and tolerability of a novel formulation of a copper-zinc malonate complex plus hydroquinone and tretinoin (Décolletage system) in the treatment of photodamaged décolletage skin.

MATERIALS AND METHODS

This prospective, randomized, placebo-controlled trial included 42 women with Fitzpatrick skin types II-IV who were randomized to receive either Décolletage system plus tretinoin 0.025% (treatment group) or tretinoin 0.05% (controls). The study was divided into two 12-week treatment periods with a 12-week follow-up period. The primary efficacy outcome measures were assessed at 4, 8, 12, and 24 weeks.

RESULTS

The results from this study show that use of the décolletage system in conjunction with tretinoin 0.025% results in significant improvements in the treatment of photodamage compared to tretinoin 0.05% alone. The improvements were observed in multiple clinical parameters, including tactile roughness, fine wrinkling, and mottled hyperpigmentation.

CONCLUSIONS

This study provides evidence that the Décolletage system, when used in combination with tretinoin 0.025%, is effective in the treatment of photodamage of the décolletage area. Further studies are needed to determine the long-term effects and safety of this formulation.

DISCLOSURE

The authors have no relevant conflicts of interest to disclose.

Support: Supported by OMP, Inc.

REFERENCES